Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug 4;60(2):2103087.
doi: 10.1183/13993003.03087-2021. Print 2022 Aug.

Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation

Karen M Olsson  1 , Manuel J Richter  2   3 , Jan C Kamp  4 , Henning Gall  2   3 , Hossein-Ardeshir Ghofrani  2   3 , Jan Fuge  4 , Ralf Ewert  5 , Marius M Hoeper  4
Affiliations
Free article
Comment

Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation

Karen M Olsson et al. Eur Respir J. .
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: K.M. Olsson has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD, Pfizer and United Therapeutics. Conflict of interest: M.J. Richter has received honoraria from Actelion, Bayer and Janssen. Conflict of interest: J.C. Kamp has nothing to disclose. Conflict of interest: H. Gall reports personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer and United Therapeutics. Conflict of interest: H-A. Ghofrani has received honoraria for consultations and/or speaking at conferences from Bayer HealthCare AG, Actelion, Encysive, Pfizer, Ergonex, Lilly and Novartis; is member of advisory boards for Acceleron, Bayer HealthCare AG, Pfizer, GSK, Actelion, Lilly, Merck, Encysive and Ergonex; has also received governmental grants from the German Research Foundation (DFG), Excellence Cluster Cardiopulmonary Research (ECCPS), State Government of Hessen (LOEWE), and the German Ministry for Education and Research (BMBF). Conflict of interest: J. Fuge has nothing to disclose. Conflict of interest: R. Ewert has received speaker fees and honoraria for consultations from Actelion, Bayer, GSK, Janssen, Lilly, MSD, Novartis, Pfizer and United Therapeutics. Conflict of interest: M.M. Hoeper has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD and Pfizer.

Comment on

  • COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
    Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Park DH, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Lange TJ, Rosenkranz S. Hoeper MM, et al. Eur Respir J. 2022 Jul 7;60(1):2102311. doi: 10.1183/13993003.02311-2021. Print 2022 Jul. Eur Respir J. 2022. PMID: 34737226 Free PMC article.
  • External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.
    Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prévot G, Chaouat A, Picard F, Horeau-Langlard D, Bourdin A, Jutant EM, Beurnier A, Jevnikar M, Jaïs X, Simonneau G, Montani D, Sitbon O, Humbert M. Boucly A, et al. Eur Respir J. 2022 Jun 30;59(6):2102419. doi: 10.1183/13993003.02419-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34737227 Free PMC article.

LinkOut - more resources